poisar

Stocks · News reference

Aurora Cannabis Urged Shareholders To Reject A Merger Bid From Curaleaf, Warning That The Hostile Bid Would Put Aurora Shareholders' Value And Future Upside At Risk

BenzingaBenzinga Newsdesk

Curaleaf's hostile and opportunistic bid significantly undervalues Aurora, and aims to capture Aurora's assets at a discountAurora is debt free and holds $149 million in cash1, Curaleaf carries over $1 billion

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. The Motley FoolJeff Siegel

    Is Aurora Cannabis Stock a Buy as Curaleaf Pushes a Hostile Takeover Bid?

    Curaleaf has launched a hostile takeover bid for Aurora Cannabis at $4 per share, which Aurora's board has rejected. While Aurora has transformed into a leaner, profitable medical cannabis company with strong international operations and a solid balance sheet, investors shouldn't buy the stock purely as a takeover bet. The company's genuine turnaround in medical cannabis and European expansion could make Curaleaf's offer undervalued, but there's no guarantee the deal will close or be increased.

    Read original at the-motley-fool